Abstract
The purpose of this study was to investigate the potential roles of the SH3-containing guanine nucleotide exchange factor (SGEF) in human prostate cancer. Experimental data showed that SGEF was overexpressed in human prostate cancer cells and specimens. The reduction of SGEF expression through an SGEF-targeting siRNA in androgen-independent C4-2 and C4-2B cells suppressed both anchorage-dependent and anchorage-independent growth. In addition, the androgen receptor (AR) antagonist bicalutamide further strengthened this inhibitory effect due to the suppression of the elevated AR transactivation after knockdown of SGEF. Collectively, our results provide the first demonstration that SGEF is a novel promoter of human prostate cancer progression and development.
Original language | English (US) |
---|---|
Pages (from-to) | 1468-1474 |
Number of pages | 7 |
Journal | Oncology reports |
Volume | 28 |
Issue number | 4 |
DOIs | |
State | Published - Oct 2012 |
Externally published | Yes |
Keywords
- AR transactivation
- Androgen receptor
- Bicalutamide
- Prostate cancer
- SGEF expression
ASJC Scopus subject areas
- Oncology
- Cancer Research